Table 4.
Performance of the predictive models.
| Signature | N | AUC (95% CI) | Sensitivity (95% CI) | Specificity (95% CI) |
|---|---|---|---|---|
| CRP | 401 | 0·85 (0·81-0·88) | 0·85 (0·81-0·88) | 0·74 (0·54-0·84) |
| HIV pos | 85 | 0·79 (0·70-0·87) | 0·83 (0·56-0·93) | 0·72 (0·39-0·83) |
| HIV neg | 316 | 0·86 (0·81-0·90) | 0·86 (0·79-0·92) | 0·70 (0·54-0·85) |
| 6-marker | 350 | 0·85 (0·80-0·90) | 0·89 (0·81-0·96) | 0·60 (0·34-0·82) |
| HIV pos | 41 | 0·80 (0·65-0·92) | 0·80 (0·65-0·95) | 0·57 (0·14-0·95) |
| HIV neg | 309 | 0·85 (0·79-0·91) | 0·88 (0·80-0·96) | 0·61 (0·29-0·85) |
| Optimal | 401 | 0·90 (0·86-0·94) | 0·93 (0·87-0·97) | 0·68 (0·36-0·82) |
| HIV pos | 85 | 0·89 (0·80-0·95) | 0·87 (0·73-1·00) | 0·64 (0·47-0·89) |
| HIV neg | 316 | 0·90 (0·86-0·94) | 0·91 (0·84-0·98) | 0·73 (0·40-0·89) |
| No Previous TB | 338 | 0·92 (0·88-0·95) | 0·94 (0·89-0·99) | 0·69 (0·36-0·87) |
| HIV pos | 64 | 0·92 (0·84-0·97) | 0·95 (0·85-1·00) | 0·64 (0·50-0·89) |
| HIV neg | 274 | 0·92 (0·87-0·96) | 0·93 (0·86-0·99) | 0·74 (0·43-0·92) |
| Previous TB | 63 | 0·83 (0·70-0·93) | 0·81 (0·67-1·00) | 0·60 (0·29-0·93) |
| HIV pos | 21 | 0·84 (0·62-0·97) | 0·70 (0·40-1·00) | 0·73 (0·27-1·00) |
| HIV neg | 42 | 0·79 (0·60-0·95) | 0·82 (0·45-1·00) | 0·68 (0·13-0·97) |
| Optimal Excluding CRP | 401 | 0·89 (0·85-0·94) | 0·92 (0·86-0·97) | 0·70 (0·47-0·84) |
| HIV pos | 85 | 0·88 (0·79-0·94) | 0·93 (0·77-1·00) | 0·56 (0·40-0·84) |
| HIV neg | 316 | 0·89 (0·84-0·93) | 0·89 (0·81-0·96) | 0·77 (0·52-0·92) |
Signatures: Six-marker (ApoA-1, CFH, CRP, IFN-γ, IP-10, SAA), optimal (I-306 and CRP), optimal excluding CRP (I-309, NCAM and SAA). N=test-set samples.